Laboratory data from the 1970s first showed that malignant melanoma

Size: px
Start display at page:

Download "Laboratory data from the 1970s first showed that malignant melanoma"

Transcription

1 2265 Survival by Radiation Therapy Oncology Group Recursive Partitioning Analysis Class and Treatment Modality in Patients with Brain Metastases from Malignant Melanoma A Retrospective Study Jeffrey C. Buchsbaum, M.D., Ph.D. 1 John H. Suh, M.D. 1 Shih-Yuan Lee, M.S.P.H. 1 Mark A. Chidel, M.D. 1 John F. Greskovich, M.D. 1 Gene H. Barnett, M.D. 2 1 Department of Radiation Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio. 2 Department of Neurosurgery, The Cleveland Clinic Foundation, Cleveland, Ohio. The authors thank The Cleveland Clinic Foundation Department of Scientific Publications and, in particular, Jessica Ancker for editorial assistance with this article. They also thank the numerous support personnel in The Cleveland Clinic Foundation Department of Radiation Oncology for assistance in collecting hospital charts. Address for reprints: John H. Suh, M.D., Department of Radiation Oncology, Desk T-28, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; Fax: (216) ; suh@radonc.ccf.org Received March 2, 2001; accepted December 23, BACKGROUND. In a population of patients with brain metastases from melanoma, the authors sought to determine whether various therapies provided any benefit at all, whether local therapy was better than whole brain radiotherapy (WBRT), and whether combined local therapy and WBRT provided any advantage over local therapy alone. They also analyzed survival according to a Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) to determine how well the RTOG RPA classes predicted survival in this patient population and whether treatments varied in effectiveness from category to category. METHODS. A total of 74 patients with brain metastases from melanoma were treated at The Cleveland Clinic Foundation between 1984 and For this study, the authors reviewed patient charts and confirmed survival status. Survival was compared by treatment modality (surgical resection, WBRT, stereotactic radiosurgery, or WBRT combined with local therapy). Survival also was compared according to the RTOG RPA prognostic classes (Class 1, Class 2, or Class 3), which has not been validated previously in patients with malignant melanoma. RESULTS. The median survival was 5.5 months for all patients. Survival varied significantly by RTOG prognostic class; The median survival was 10.5 months (range, months) for patients in Class 1, 5.9 months (range, months) for patients in Class 2, and 1.8 months (range, months) for patients in Class 3 (P ). Survival analysis showed that combined treatment offered significantly better survival (P ; combined vs. other). The median survival was 8.8 months (range, months) for the combined therapy group, 4.8 months (range, months) for the local therapy alone group, 2.3 months (range, months) for the WBRT alone group, and 1.1 months ( months) for the group that received no therapy. CONCLUSIONS. Adding WBRT to local therapy may improve survival in this group of patients: Combined therapy was superior to WBRT alone. The RPA classification scheme likely has prognostic value for patients with brain metastases from malignant melanoma. Prospective studies are required to overcome selection bias and confirm these results. Cancer 2002;94: American Cancer Society. DOI /cncr KEYWORDS: malignant melanoma, whole brain radiotherapy, radiosurgery, brain metastases, recursive partitioning analysis, selection bias. Laboratory data from the 1970s first showed that malignant melanoma cell lines were highly radioresistant, 1 but clinical data on the role of radiation for patients with brain metastases from malignant 2002 American Cancer Society

2 2266 CANCER April 15, 2002 / Volume 94 / Number 8 melanoma are conflicting and of limited power. For example, one study found that radiation was palliative for a small number of patients, regardless of the number of metastases. 2 Conversely, some studies have suggested that melanomas have better response to radiosurgery than adenocarcinomas. 3,4 Whole brain radiotherapy (WBRT) does not appear to increase the efficacy of stereotactic radiosurgery (SRS) in patients with brain metastases from malignant melanoma. 5 Overall, radiation is effective for symptom control in patients with brain metastases from malignant melanoma. 6 However, a large 1998 review found no significant difference in survival between patients who received postoperative radiotherapy and patients who did not. 7 This finding was confirmed in a review of surgical patients at Memorial Sloan-Kettering. 8 In addition, debate continues about the applicability of the prognostic classification developed by the Radiation Therapy Oncology Group (RTOG) for patients with brain metastases. The RTOG algorithm was based primarily on data from patients with metastatic breast and lung carcinoma, and its prognostic value has not been assessed widely in patients with brain metastases from malignant melanoma. To provide further depth to the literature on this controversial topic, we analyzed the results from our institution s patients with brain metastases from malignant melanoma who were treated with linear accelerator-based radiosurgery (LINAC RS), gamma knife radiosurgery, or surgery. We sought to determine whether these therapies provided any benefit at all, whether local therapy was better than WBRT, and whether combined local therapy and WBRT provided any advantage. We also analyzed survival according to the RTOG recursive partitioning analysis (RPA) classes to determine how well these classes predicted survival in this patient population and whether treatments varied in effectiveness from class to class. MATERIALS AND METHODS Patient Sample We screened our departmental data base and The Cleveland Clinic Foundation s main data base for all records of patients with malignant melanoma who were treated for brain metastases. In all patients, treatment decisions were made by the physician and the patient; no algorithm or randomization was used. All patients received follow-up care at our institution. None had prior cranial malignancies. Diagnoses were confirmed radiographically with computed tomography (CT) scans or magnetic resonance imaging (MRI), except in several patients whose diagnoses were confirmed by surgical biopsy. No patients were excluded. Data Collection Data were collected from departmental and hospital charts and telephone interviews. If survival status was not clear in the medical records, then we contacted patients, families, or physicians by telephone or checked the patient s status in the United States Social Security data base. The data collected included age, gender, Karnofsky performance score (KPS) at diagnosis, symptom profile, location of lesion, number of lesions, size of lesions, histology, staging at initial diagnosis, dates of all procedures, dose of radiation used, type of resection (subtotal or macroscopic total), length of hospital stay, length of steroid usage/dependency, complications, cause of death, and date of death. Patient data were acquired and used following the guidelines set forth by our Institutional Review Board, which approved this study. Statistical Techniques We used the RTOG method 9 to assign prognostic classes to patients with brain metastases. The method uses RPA based on the KPS, primary lesion status, presence of extracranial metastases, and age. Patients were assigned to Class 1 (best prognosis), Class 2, or Class 3 (worst prognosis). For all patients, survival was assessed as of April 1, Actuarial data were evaluated and plotted using the Kaplan Meier method, and significance was evaluated using Cox Mantel log-rank tests for single variable comparisons and Cox proportional hazards for multivariate comparisons. The median survival is reported with the range in parentheses after the presented value. Statistical significance was defined as P 0.05 (two tailed). All statistical evaluations were conducted with the assistance of the statistical software packages JMP (version 3.2.1) and StatView (version 5.0; SAS Institute, Cary, NC). 10 Treatment Delivery Radiation therapy The methods of radiation delivery varied over time. LINAC RS was used for SRS until December The gamma knife has been used for SRS since January WBRT was performed with megavoltage-based external beam radiotherapy. Patients were simulated using standard techniques and were treated in various fractionation schemes using opposed lateral fields. In some patients, adjunct chemotherapy was added to surgery or radiation therapy. Fraction size varied from 180 centigrays (cgy) to 550 cgy, and fractions were given one per day in all patients. The total dose varied from 22 grays (Gy) to 55 Gy. The majority of patients who received WBRT (29 of 61 patients) were treated with fractions of 300 cgy for a total dose of 30 Gy. SRS

3 Survival in Malignant Melanoma Brain Metastases/Buchsbaum et al TABLE 1 Characteristics of 74 Patients Treated for Brain Metastases from Melanoma Characteristic No treatment (n 3 patients) WBRT alone (n 25 patients) Local therapy alone WBRT with local therapy (n 10 patients) a (n 36 patients) a P value Gender (%) Male 1 (33) 21 (84) 6 (60) 25 (69) Female 2 (67) 4 (16) 4 (40) 11 (31) Age in yrs (%) 65 1 (33) 17 (68) 8 (80) 30 (82) (67) 8 (32) 2 (20) 6 (18) KPS (%) 70 3 (100) 10 (40) 0 (0) 0 (0) b 70 0 (0) 15 (60) 10 (100) 36 (100) Primary tumor controlled (%) Yes 2 (67) 17 (68) 7 (70) 35 (97) b No 1 (33) 8 (32) 3 (30) 1 (3) Systemic disease (%) Yes 2 (67) 20 (80) 7 (70) 22 (61) No 1 (33) 5 (20) 3 (30) 14 (39) Location of other metastases Liver Lung Bone Other Single lesion (%) Yes 2 (67) 3 (12) 6 (60) 16 (44) b No 1 (33) 22 (88) 4 (40) 20 (56) Solitary lesion (%) Yes 1 (33) 3 (12) 1 (10) 9 (25) No 2 (67) 22 (88) 9 (90) 27 (75) Stage (%) I 1 (33) 2 (8) 1 (10) 4 (11) II 2 (67) 11 (44) 2 (20) 7 (19) III 0 (0) 3 (12) 4 (40) 10 (28) IV 0 (0) 9 (36) 3 (30) 15 (42) RTOG RPA classes 1 0 (0) 0 (0) 1 (10) 11 (30) b 2 c 0 (0) 12 (48) 6 (60) 24 (67) 2 0 (0) 3 (12) 3 (30) 1 (3) 3 3 (100) 10 (40) 0 (0) 0 (0) Median age in yrs (range) 67 (32 84) 54 (40 86) 49 (31 73) 53 (27 78) Median KPS (range) 30 (10 50) 70 (30 100) 90 (70 100) 90 (70 100) b Median lesion numbers (range) 1 (1 10) 3 (1 25) 1 (1 6) 2 (1 6) b Median maximum greatest dimension in cm (range) 1 ( ) 2 ( ) 2 ( ) 2.5 ( ) WBRT indicates whole brain radiotherapy; RTOG indicates Radiation Therapy Oncology Group; RPA: recursive partitioning analysis. a Local therapy was either surgery or radiosurgery with either Linac or Gamma Knife. b Represents data with P c RTOG Group 2 was broken up into Group 2 and Group 2 with the latter group comprised of patients with controlled primary lesions. dosing varied from 15 Gy to 25 Gy in one fraction, and gamma knife dosing followed standard RTOG guidelines, which are based on the greatest lesion dimension. Surgery Standard craniotomy technique was used to remove the lesions. Resection was either macroscopic total resection or subtotal resection. Biopsy-only procedures of cranial lesions were considered subtotal resection. Complications within 30 days of surgery were attributed to surgery if they appeared to be unrelated to a prior medical condition. RESULTS In 74 of 1154 patients (6.4%) with brain metastases who were treated at The Cleveland Clinic between 1984 and 1998, the histologic diagnosis was malignant melanoma. Table 1 shows the characteristics of this patient sample.

4 2268 CANCER April 15, 2002 / Volume 94 / Number 8 FIGURE 1. Kaplan Meier analysis of survival by treatment group (survival is outlined fully in Table 2). The difference between patients in the group that received combined therapy and patients in any of the other three treatment groups was statistically significant (P ). The diamonds represent patients who were living at the time of this report. The median survival for each therapy group is shown. The differences between the combined treatment group and the other groups were statistically significant (P ). WBRT: whole brain radiotherapy. There were more male patients than female patients. Stage was distributed as shown. The distribution of other sites of metastases is shown, and some patients had more than one site of metastasis. Chemotherapy was not used in the vast majority of the patients, and, when it was, a large number of different agents were used. Survival The median survival for all patients was 5.5 months (range, months). Patients were stratified into four treatment groups for survival analysis: those who received no therapy (n 3 patients), those who received local therapy only (surgery or SRS; n 10 patients), those who received WBRT alone (n 25 patients), and those who received local therapy (surgery or SRS) combined with WBRT (n 36 patients). In the combined group, 14 patients underwent surgery and WBRT; 19 patients underwent SRS and WBRT; and 3 patients underwent SRS, surgery, and WBRT: Survival of patients in these three subgroups of the combined arm were 11.3 months, 12.3 months, and 13.1 months, respectively. Figure 1 shows that survival in the combination therapy patients was significantly better compared with survival in the other three treatment categories grouped together (P 0.001). Comparison of the SRS and WBRT group with the surgery and WBRT group demonstrated no significant difference (P ). The median survival for patients with melanoma who did not receive any adjuvant therapy was 1.1 months (range, months). For patients who received either surgery or SRS without WBRT, the median survival was 4.8 months (range, months). For patients who received WBRT only, the median survival was 2.3 months (range, months). For patients who received both WBRT and local therapy (SRS or surgery), the median survival was 8.8 months (range, months). Fraction size and total radiation dose did not significantly affect survival in the patients who received WBRT alone or in combination with other therapy. Fraction size did not affect survival in patients who received either SRS or WBRT. A second analysis was performed to compare survival by RTOG RPA class. Survival differences were statistically significant among the groups (P ). The data are shown in Figures 2 and 3. The median survival was 10.5 months (range, months) for RPA Class 1 patients, 5.9 months (range, months) for RPA Class 2 patients, and 1.8 months (range, months) for RPA Class 3 patients (P for Class 1 vs. Class 2 vs. Class 3 in all combinations). The role of chemotherapy was not evaluated in this study and was used in a minority of our patients, often as part of a protocol. Log-rank univariate and proportional hazards multivariate analyses of the data are summarized in Tables 2 4. Significant factors on log-rank analysis included control of the primary lesion, single lesion status, solitary lesion status, RTOG RPA class, surgery, and treatment group. On univariate log-rank analysis, control of the primary lesion, single lesion status, solitary lesion status, RPA class, surgery group, SRS group, and treatment group were statistically significant. On univariate proportional hazards analysis, it was found that KPS was significant, whereas greatest lesion dimension (almost significant), fraction size during WBRT, and the number of lesions were not significant. On multivariate proportional hazards analysis, control of systemic disease, KPS, and treatment group were significant. There was a significant difference between patients who were treated with local therapy alone and patients who were treated with local therapy plus WBRT. There was a significant correlation between treatment group and RPA class, as shown in Table 1.

5 Survival in Malignant Melanoma Brain Metastases/Buchsbaum et al FIGURE 2. Kaplan Meier analysis of survival by Radiation Therapy Oncology Group recursive partitioning analysis class (survival is outlined fully in Table 2). The difference between the three curves was statistically significant (P ). The diamonds represent patients who were living at the time of this report. FIGURE 3. Kaplan Meier analysis of survival according to the modified Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) Class. RPA Class 2 was split into two groups, patients with controlled primary lesions (Class 2 ) and patients without controlled primary lesions (Class 2 ). The diamonds represent patients who were living at the time of this report. Only eight patients did not have control of their primary lesion at the time they were diagnosed with brain metastasis and otherwise met the criteria for RTOG RPA Group 2. The differences between Classes 1, 2, 2, and 3 were not formally significant as a whole according to a Wald analysis (see Table 4) due to the small numbers, although Class 1 differed significantly from Class 3 (P ). Local and Regional Control Of 74 patients, 25 patients had failure of local control within the brain confirmed by CT or MRI scan data after the treatment was delivered. A total of 52 patients received follow-up CT or MRI scans. In all patients, local recurrence was accompanied by concurrent systemic recurrence or progression. Local cranial recurrence occurred in 2 of 10 patients (20%) who received local therapy only (surgery or SRS), in 4 of 24 patients (17%) who received WBRT only, and in 18 of 37 patients (49%) who received local therapy combined with WBRT. Scans were ordered based on clinical suspicion of recurrent disease without set guidelines. These data likely reflect the fact that patients who are treated aggressively may be more likely to be scanned with the onset of new symptoms. In our series, 18 of 25 follow-up scans were performed for patients who received local therapy combined with WBRT.

6 2270 CANCER April 15, 2002 / Volume 94 / Number 8 TABLE 2 Univariate Kaplan Meier Survival Analysis in 74 Patients Variable No. of patients Medial survival in months (range) Standard error Log-rank P value Gender Men ( ) Women ( ) Age (yrs) ( ) a ( ) KPS ( ) a ( ) Stage I ( ) II ( ) III ( ) IV ( ) Control of primary lesion Yes ( ) a No ( ) Systemic (with other metastases) Yes ( ) No ( ) Single lesion Yes ( ) a No (0.2 60) Solitary lesion Yes ( ) a No ( ) RTOG RPA class ( ) a ( ) ( ) ( ) WBRT Yes ( ) No ( ) SRS Yes ( ) a No ( ) SRS type Gamma knife ( ) Linac ( ) Surgery Yes ( ) a No ( ) Extent of resection Subtotal ( ) Macroscopic total ( ) Treatment group No treatment (0.1 81) a WBRT only ( ) Local therapy (surgery or SRS) only ( ) Local therapy plus WBRT ( ) KPS: Karnofsky performance status; RTOG: Radiation Therapy Oncology Group; RPA: recursive partitioning analysis; WBRT: whole brain radiotherapy; SRS: radiosurgery. a Represents data with P Complications Ten of 70 patients who were treated with either SRS or WBRT experienced an acute complication: swelling requiring increased steroid dosing in 9 patients and seizure in 1 patient, which was controlled with medication. No radiation patients had symptomatic radiation necrosis as a side effect. Of 25 patients who underwent surgery alone or with WBRT, 6 patients had acute complications requiring admission to hospital: One patient had an infection, 2 patients had hemorrhages, and 3 patients had new central nervous system deficits. No cerebrospinal fluid leaks were caused by surgery. No surgical patient had long-term complications. At 1 month after treatment, 6 of 70 living patients still were using steroids. By 3 months, two of these patients still were using steroids, and two additional patients had begun using steroids. DISCUSSION The current data suggest that 1) patients in RTOG RPA Class 1 were more likely to be treated aggressively with combination WBRT and a local therapy (SRS or surgery), 2) combination therapy in the context of patient selection is superior to either local therapy alone or WBRT alone, 3) local therapy increases survival relative to WBRT if selection bias is ignored, and 4) patients with brain metastases from melanoma have poor survival if they present with poor RTOG RPA class. This is in agreement with a recent evaluation 11 of the RTOG RPA classification that validated the approach for historic comparisons based on RTOG The data in Tables 1 and 2 show clearly that treatment was correlated significantly with RPA class and that RPA class was correlated significantly with survival. Inherent in any nonrandomized study is the problem of selection bias. Much of the survival benefit of combination therapy (Fig. 1) likely was due to this bias. This critical point was explored by Gaspar et al., 9 who came to a similar conclusion: Patient selection plays a critical role in survival in brain metastases research series. This conclusion was reinforced indirectly in the RTOG RPA validation article due to the small numbers of Class 3 patients that were included. 11 The current data are similar to those reported by Kondziolka et al., who found that combined SRS and WBRT controlled disease better and possibly improved survival compared with WBRT alone. 12 This is in contrast to results published by Mori et al., who found that WBRT combined with SRS/surgery offers no benefit. 13 Although our series was not randomized like the series reported by Kondziolka et al., we had similar results and had relatively large numbers of patients who were treated with combined modalities

7 Survival in Malignant Melanoma Brain Metastases/Buchsbaum et al TABLE 3 Univariate Proportional Hazards Analysis of Continuous Variables Affecting Survival in Patients with Brain Metastases from Melanoma Category Coefficient ( ) Standard error Wald Chi-square Hazard ratio (95% CI) P value Age at diagnosis (increase in risk for each year increase) ( ) KPS at diagnosis (decrease in risk for each 10-point increase) ( ) a No. of lesions at diagnosis (increase in risk with each additional lesion) ( ) Greatest dimension of largest lesion (decrease in risk for each additional cm in greatest dimension) ( ) WBRT fractions (decrease in risk for each number of fraction increase) WBRT alone ( ) WBRT and local therapy ( ) % CI: 95% confidence interval; KPS: Karnofsky performance status; WBRT: whole brain radiotherapy. a Represents data with P TABLE 4 Multivariate Proportional Hazards Analysis of Variables Affecting Survival in Patients with Brain Metastases from Melanoma Parameter Coefficient ( ) Standard error Hazard ratio (95% CI) P value Wald globle test (P value) Model 1 Age in yrs ( 65 vs. 65) ( ) KPS ( 70 vs. 70) ( ) a Control of primary tumor (no vs. yes) ( ) Systemic (no vs. yes) ( ) a Single (no vs. yes) ( Treatment group (vs. local therapy and WBRT) No treatment ( ) a WBRT only ( ) a Local therapy (SRS or surgery) only ( ) Model 2 RTOG RPA class (vs. RPA Class 3) ( ) a ( ) a ( ) Single (no vs. yes) ( ) Treatment group (vs. local therapy and WBRT) ( ) a No treatment ( ) a WBRT only ( ) Local therapy (SRS or surgery) only 95% CI: 95% confidence interval; KPS: Karnofsky performance status; WBRT: whole brain radiotherapy; SRS: radiosurgery; RTOG: Radiation Therapy Oncology Group; RPA: recursive partitioning analysis. a Represents data with P (n 37 patients) using the current technology. We also had more patients with melanoma than their total of five patients (three in the WBRT alone arm and two in the combined arm). Despite concerns regarding the radioresistance of melanoma, WBRT in our patient sample may be important, because it affected subclinical disease when local therapy (SRS/surgery) was used to control areas of macroscopic disease. Looking at WBRT results alone in log-rank fashion (see Table 2), WBRT was significant for survival. However, it is clear from our data that combined therapy was superior to WBRT alone, and the Kaplan Meier curves for survival suggest that combined therapy is better than local therapy alone. Our multivariate data show a difference between combined therapy and local therapy. If surgery and SRS are considered therapies that boost the effectiveness of WBRT, then the combined treatment simply modulates dose relative to tumor cell density. This perspective raises the question of using intensitymodulated radiation therapy (IMRT) in patients who are eligible for local therapy combined with WBRT,

8 2272 CANCER April 15, 2002 / Volume 94 / Number 8 designing treatment plans that boost the dose to larger lesions to SRS-like doses. It also raises the question regarding the timing of WBRT: up front or in reserve? 14,15 In finding prognostic significance in a population of patients with melanoma, our study addresses previous criticism that the RPA categories are based primarily on patients with carcinoma of the breast and lung. 4,11,16,17 When we performed an additional analysis of our patients using the modification of the RPA proposed by Nieder et al. at the M. D. Anderson Cancer Center, we found that, just as Nieder et al. suggested, RPA Class 2 could be divided into two subgroups according to survival (Fig. 3). Multivariate analysis (Table 4) showed that control of the primary lesion was significant in its effects on survival. This is in agreement with the data reported by Nieder et al., who showed that the RPA classification identified patients in RPA Class 2 who should be treated aggressively. 18 There were seven patients in the no control at primary site category, as shown in Table 1 (RTOG RPA Class 2) and could not be shown to differ from RTOG RPA Class 3 (see Table 4, Fig. 3). Our data do lend credence to the assertion that the survival of patients in RPA Class 2 may be bimodal. CONCLUSIONS The most striking finding in the data is that clinicians as a whole had selected patients for treatment in a fashion that correlated with the RTOG RPA schema. In a similar fashion, at first, the observation is troubling that the patients who survived the longest had an almost 50% cranial failure rate, whereas the other groups had cranial failure rates 20%. This finding may be explained by the fact that patients who survive longer may have more time to develop failure of local control. Alternately, the estimate of the local recurrence rate may have been inflated by the fact that these patients were evaluated more rigorously than other patient groups, such as hospice patients. It is unclear whether WBRT should be held in reserve or given at the same time as local therapy, and this issue needs to be evaluated in a prospective fashion. The RTOG RPA classes are likely to be valid for patients with metastatic melanoma based on our data review. The role of local control of the primary lesion and how it is correlated strongly with RPA Group 2 survival, as discussed by Nieder et al., 18 will need to be examined further in a prospective fashion. The use of IMRT to mimic both WBRT and SRS also is an interesting issue to be addressed in future studies. REFERENCES 1. Barranco S, Romsdahl M, Humphrey R. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res. 1971;31: Konefal JB, Emami B, Pilepich MV. Analysis of dose fractionation in the palliation of metastases from malignant melanoma. Cancer. 1988;61(2): Shiau CY, Sneed PK, Shu HK, et al. Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control. Int J Radiat Oncol Biol Phys. 1997; 37(2): Seung SK, Sneed PK, McDermott MW, et al. Gamma knife radiosurgery for malignant melanoma brain metastases [see comments]. Cancer J Sci Am. 1998;4(2): Young RF. Radiosurgery for the treatment of brain metastases. Semin Surg Oncol. 1998;14(1): Carella RJ, Gelber R, Hendrickson F, Berry HC, Cooper JS. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II. Cancer. 1980;45(4): Sampson JHC Jr., Friedman AH, Siegler HF. Demographics, prognosis and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88(1): Wronski M, Arbit E. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. J Neurosurg. 2000;93(1): Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4): SAS Institute. JMP, edition Cary: SAS Institute, Gaspar LE, Scott C, Murray K, Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys. 2000;47(4): Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45(2): Mori Y, Kondziolka D, Flickinger JC, Kirkwood JM, Agarwala S, Lunsford LD. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys. 1998;42(3): Chidel MA, Suh JH, Reddy CA, Chao ST, Lundbeck MF, Barnett GH. Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys. 2000;47(4): Chidel MA, Suh JH, Greskovich JF, Kupelian PA, Barnett GH. Treatment outcome for patients with primary nonsmall-cell lung cancer and synchronous brain metastasis. Radiat Oncol Invest. 1999;7(5): Williams J, Enger C, Wharam M, Tsai D, Brem H. Stereotactic radiosurgery for brain metastases: comparison of lung carcinoma vs. non-lung tumors. J Neurooncol. 1998;37(1): Wronski M, Maor MH, Davis BJ, Sawaya R, Levin VA. External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 1997;37(4): Nieder C, Nestle U, Motaref B, Walter K, Niewald M, Schnabel K. Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes? Int J Radiat Oncol Biol Phys. 2000;46(2):

A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia

A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,

More information

Research Article Have Changes in Systemic Treatment Improved Survival in Patients with Breast Cancer Metastatic to the Brain?

Research Article Have Changes in Systemic Treatment Improved Survival in Patients with Breast Cancer Metastatic to the Brain? Oncology Volume 2008, Article ID 417137, 5 pages doi:10.1155/2008/417137 Research Article Have Changes in Systemic Treatment Improved Survival in Patients with Breast Cancer Metastatic to the Brain? Carsten

More information

Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases

Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases ONCOLOGY REPORTS 29: 407-412, 2013 Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases SHELLY LWU 1, PABLO GOETZ 1, ERIC MONSALVES 1, MANDANA ARYAEE 1, JULIUS

More information

Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin

Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin J Neurosurg 104:907 912, 2006 Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin MICHAEL A. VOGELBAUM, M.D., PH.D., LILYANA ANGELOV, M.D., SHIH-YUAN

More information

Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery

Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery ORIGINAL ARTICLE Survival and Intracranial Control of Patients With 5 or More Brain Metastases Treated With Gamma Knife Stereotactic Radiosurgery Ann C. Raldow, BS,* Veronica L. Chiang, MD,w Jonathan P.

More information

Nonsmall Cell Lung Cancer Presenting with Synchronous Solitary Brain Metastasis

Nonsmall Cell Lung Cancer Presenting with Synchronous Solitary Brain Metastasis 1998 Nonsmall Cell Lung Cancer Presenting with Synchronous Solitary Brain Metastasis Chaosu Hu, M.D. 1 Eric L. Chang, M.D. 2 Samuel J. Hassenbusch III, M.D., Ph.D. 3 Pamela K. Allen, Ph.D. 2 Shiao Y. Woo,

More information

A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma

A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma British Journal of Cancer (4) 91, 829 833 All rights reserved 7 9/4 $3. www.bjcancer.com A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic

More information

Outcome of Surgical Resection of Symptomatic Cerebral Lesions in Non-Small Cell Lung Cancer Patients with Multiple Brain Metastases

Outcome of Surgical Resection of Symptomatic Cerebral Lesions in Non-Small Cell Lung Cancer Patients with Multiple Brain Metastases ORIGIL ARTICLE Brain Tumor Res Treat 2013;1:64-70 / Print ISSN 2288-2405 / Online ISSN 2288-2413 online ML Comm Outcome of Surgical Resection of Symptomatic Cerebral Lesions in Non-Small Cell Lung Cancer

More information

Management of single brain metastasis: a practice guideline

Management of single brain metastasis: a practice guideline PRACTICE GUIDELINE SERIES Management of single brain metastasis: a practice guideline A. Mintz MD,* J. Perry MD, K. Spithoff BHSc, A. Chambers MA, and N. Laperriere MD on behalf of the Neuro-oncology Disease

More information

Prognostic Factors for Survival in Patients Treated With Stereotactic Radiosurgery for Recurrent Brain Metastases After Prior Whole Brain Radiotherapy

Prognostic Factors for Survival in Patients Treated With Stereotactic Radiosurgery for Recurrent Brain Metastases After Prior Whole Brain Radiotherapy International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation: Metastases Prognostic Factors for Survival in Patients Treated With Stereotactic Radiosurgery for

More information

Neurological Change after Gamma Knife Radiosurgery for Brain Metastases Involving the Motor Cortex

Neurological Change after Gamma Knife Radiosurgery for Brain Metastases Involving the Motor Cortex ORIGINAL ARTICLE Brain Tumor Res Treat 2016;4(2):111-115 / pissn 2288-2405 / eissn 2288-2413 http://dx.doi.org/10.14791/btrt.2016.4.2.111 Neurological Change after Gamma Knife Radiosurgery for Brain Metastases

More information

We have previously reported good clinical results

We have previously reported good clinical results J Neurosurg 113:48 52, 2010 Gamma Knife surgery as sole treatment for multiple brain metastases: 2-center retrospective review of 1508 cases meeting the inclusion criteria of the JLGK0901 multi-institutional

More information

Clinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases

Clinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases Clinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases Ying Zhou 1#, Kefang Zhong 1#, Fang Zhou* 2 ABSTRACT This paper aims to explore the clinical features and prognostic

More information

SUCCESSFUL TREATMENT OF METASTATIC BRAIN TUMOR BY CYBERKNIFE: A CASE REPORT

SUCCESSFUL TREATMENT OF METASTATIC BRAIN TUMOR BY CYBERKNIFE: A CASE REPORT SUCCESSFUL TREATMENT OF METASTATIC BRAIN TUMOR BY CYBERKNIFE: A CASE REPORT Cheng-Ta Hsieh, 1 Cheng-Fu Chang, 1 Ming-Ying Liu, 1 Li-Ping Chang, 2 Dueng-Yuan Hueng, 3 Steven D. Chang, 4 and Da-Tong Ju 1

More information

Evidence Based Medicine for Gamma Knife Radiosurgery. Metastatic Disease GAMMA KNIFE SURGERY

Evidence Based Medicine for Gamma Knife Radiosurgery. Metastatic Disease GAMMA KNIFE SURGERY GAMMA KNIFE SURGERY Metastatic Disease Evidence Based Medicine for Gamma Knife Radiosurgery Photos courtesy of Jean Régis, Timone University Hospital, Marseille, France Brain Metastases The first report

More information

The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.

The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D. The Role of Radiation Therapy in the Treatment of Brain Metastases Matthew Cavey, M.D. Objectives Provide information about the prospective trials that are driving the treatment of patients with brain

More information

Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13

Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13 Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms Jason Sheehan, MD, PhD Departments of Neurosurgery and Radiation Oncology University of Virginia, Charlottesville, VA USA Overall

More information

Brain metastases are common brain malignant neoplasms

Brain metastases are common brain malignant neoplasms J Neurosurg (Suppl) 117:49 56, 2012 Hypofractionated stereotactic radiotherapy with or without whole-brain radiotherapy for patients with newly diagnosed brain metastases from non small cell lung cancer

More information

Stage III non small cell lung cancer and metachronous brain metastases

Stage III non small cell lung cancer and metachronous brain metastases General Thoracic Surgery Stage III non small cell lung cancer and metachronous brain metastases Nader Moazami, MD a Thomas W. Rice, MD a Lisa A. Rybicki, MS b David J. Adelstein, MD c Sudish C. Murthy,

More information

Br a i n metastases occur in 20 40% of all patients. The results of resection after stereotactic radiosurgery for brain metastases.

Br a i n metastases occur in 20 40% of all patients. The results of resection after stereotactic radiosurgery for brain metastases. J Neurosurg 111:825 831, 2009 The results of resection after stereotactic radiosurgery for brain metastases Clinical article Hi d e y u k i Ka n o, M.D., Ph.D., 1,3 Do u g l a s Ko n d z i o l k a, M.D.,

More information

STEREOTACTIC RADIOSURGERY FOR LIMITED BRAIN METASTASES IN IRANIAN BREAST CANCER PATIENTS

STEREOTACTIC RADIOSURGERY FOR LIMITED BRAIN METASTASES IN IRANIAN BREAST CANCER PATIENTS STEREOTACTIC RADIOSURGERY FOR LIMITED BRAIN METASTASES IN IRANIAN BREAST CANCER PATIENTS Yousefi Kashi A. SH, Mofid B. 1 Department of Radiation Oncology,Shohada Tajrish Hospital,Shahid Beheshti University

More information

Original Article Value of Adding Boost to Whole Brain Radiotherapy after Surgical Resection of Limited Brain Metastases

Original Article Value of Adding Boost to Whole Brain Radiotherapy after Surgical Resection of Limited Brain Metastases Egyptian Journal of Neurosurgery Volume 29 / No. 4 / October - December 2014 39-44 Original Article Value of Adding Boost to Whole Brain Radiotherapy after Surgical Resection of Limited Brain Metastases

More information

Gamma Knife Surgery for Brain Metastasis from Renal Cell Carcinoma : Relationship Between Radiological Characteristics and Initial Tumor Response

Gamma Knife Surgery for Brain Metastasis from Renal Cell Carcinoma : Relationship Between Radiological Characteristics and Initial Tumor Response online ML Comm www.jkns.or.kr Clinical Article Jin Wook Kim, M.D. Jung Ho Han, M.D. Chul-Kee Park, M.D. Hyun-Tai Chung, Ph.D. Sun Ha Paek, M.D. Dong Gyu Kim, M.D. Department of Neurosurgery Seoul National

More information

Department of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway 2

Department of Oncology and Palliative Medicine, Nordland Hospital, 8092 Bodø, Norway 2 The Scientific World Journal Volume 212, Article ID 69323, 5 pages doi:1.11/212/69323 The cientificworldjournal Clinical Study Towards Improved Prognostic Scores Predicting Survival in Patients with Brain

More information

JAMA. 2006;295:

JAMA. 2006;295: ORIGINAL CONTRIBUTION Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases A Randomized Controlled Trial Hidefumi Aoyama, MD,

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM BRAIN METASTASES CNS Site Group Brain Metastases Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION

More information

Tr a d i t i o n a l ly, WBRT has been the standard approach

Tr a d i t i o n a l ly, WBRT has been the standard approach Neurosurg Focus 27 (6):E7, 2009 Stereotactic radiosurgery boost to the resection bed for oligometastatic brain disease: challenging the tradition of adjuvant whole-brain radiotherapy Br i a n J. Ka r l

More information

Outcomes in patients with brain metastasis from esophageal carcinoma

Outcomes in patients with brain metastasis from esophageal carcinoma Original Article Outcomes in patients with brain metastasis from esophageal carcinoma Nishi Kothari 1, Eric Mellon 2, Sarah E. Hoffe 2, Jessica Frakes 2, Ravi Shridhar 3, Jose Pimiento 1, Ken Meredith

More information

RESEARCH HUMAN CLINICAL STUDIES

RESEARCH HUMAN CLINICAL STUDIES TOPIC RESEARCH HUMAN CLINICAL STUDIES RESEARCH HUMAN CLINICAL STUDIES Radiosurgery to the Surgical Cavity as Adjuvant Therapy for Resected Brain Metastasis Jared R. Robbins, MD* Samuel Ryu, MD* Steven

More information

Optimal Management of Isolated HER2+ve Brain Metastases

Optimal Management of Isolated HER2+ve Brain Metastases Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not

More information

Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased

Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased analysis Roel Schlijper Fellow Radiation Oncology BC Cancer, Prince George Disclosures No conflicts

More information

Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases

Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases clinical article J Neurosurg 123:1261 1267, 2015 Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases *Jessica M. Frakes, MD,

More information

VINCENT KHOO. 8 th EIKCS Symposium: May 2013

VINCENT KHOO. 8 th EIKCS Symposium: May 2013 8 th EIKCS Symposium: May 2013 VINCENT KHOO Royal Marsden NHS Foundation Trust & Institute of Cancer Research St George s Hospital & University of London Austin Health & University of Melbourne Disclosures

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation

More information

Radiotherapy and Brain Metastases. Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem

Radiotherapy and Brain Metastases. Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem Radiotherapy and Brain Metastases Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem 24-02-2017 Possible strategies Watchful waiting Surgery Postop RT to resection cavity or WBRT postop SRS

More information

Hong Kong Hospital Authority Convention 2018

Hong Kong Hospital Authority Convention 2018 Hong Kong Hospital Authority Convention 2018 Stereotactic Radiosurgery in Brain Metastases - Development of the New Treatment Paradigm in HA, Patients Profiles and Their Clinical Outcomes 8 May 2018 Dr

More information

PROCARBAZINE, lomustine, and vincristine (PCV) is

PROCARBAZINE, lomustine, and vincristine (PCV) is RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine

More information

Management of Single Brain Metastases Practice Guideline Report #9-1

Management of Single Brain Metastases Practice Guideline Report #9-1 Management of Single Brain Metastases Practice Guideline Report #9-1 A.P. Mintz, J. Perry, G. Cairncross, A. Chambers and members of the Neuro-oncology Disease Site Group Report Date: August 17, 2004 SUMMARY

More information

Tania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015

Tania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015 Tania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015 Most common brain tumor, affecting 8.5-15% of cancer patients. Treatment options: Whole brain radiation

More information

Hypofractionated radiation therapy for glioblastoma

Hypofractionated radiation therapy for glioblastoma Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health

More information

Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumoral hemorrhage on survival

Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumoral hemorrhage on survival J Neurosurg J Neurosurg (Suppl) 109:000 000, 109:99 105, 2008 Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumoral hemorrhage on survival And y J. Re d m o n d, M.D.,

More information

Treatment of Recurrent Brain Metastases

Treatment of Recurrent Brain Metastases Treatment of Recurrent Brain Metastases Penny K. Sneed, M.D. Dept. of Radiation Oncology University of California San Francisco Background Brain metastases occur in 8.5-15% of cancer pts in population-

More information

Palliative radiotherapy in lung cancer

Palliative radiotherapy in lung cancer New concepts and insights regarding the role of radiation therapy in metastatic disease Umberto Ricardi University of Turin Department of Oncology Radiation Oncology Palliative radiotherapy in lung cancer

More information

Outcomes after Reirradiation for Brain Metastases

Outcomes after Reirradiation for Brain Metastases Original Article PROGRESS in MEDICAL PHYSICS Vol. 26, No. 3, September, 2015 http://dx.doi.org/10.14316/pmp.2015.26.3.137 Outcomes after Reirradiation for Brain Metastases Jesang Yu, Ji Hoon Choi, Sun

More information

Liang-Hua Ma, Guang Li *, Hong-Wei Zhang, Zhi-Yu Wang, Jun Dang, Shuo Zhang and Lei Yao

Liang-Hua Ma, Guang Li *, Hong-Wei Zhang, Zhi-Yu Wang, Jun Dang, Shuo Zhang and Lei Yao Ma et al. Radiation Oncology (2016) 11:92 DOI 10.1186/s13014-016-0667-x RESEARCH Open Access The effect of non-small cell lung cancer histology on survival as measured by the graded prognostic assessment

More information

Selecting the Optimal Treatment for Brain Metastases

Selecting the Optimal Treatment for Brain Metastases Selecting the Optimal Treatment for Brain Metastases Clinical Practice Today CME Co-provided by Learning Objectives Upon completion, participants should be able to: Understand the benefits, limitations,

More information

!"#$%&'()*+,-./01 !"#$ N! !"#$%&'()*+,- !"#$%&'()*+,-)*./01!"#$% &'()*+,-./#0!"#$#%

!#$%&'()*+,-./01 !#$ N! !#$%&'()*+,- !#$%&'()*+,-)*./01!#$% &'()*+,-./#0!#$#% !"#$%&!"#$ N!!"#$%&'()!" N!!"#$%&'()*+,-./0123456789:;4567 OMN!"#$%!&!"#$%&'!( )*+,-./01!2345678019:;?@!ABC%6 2!"#$%&'()*!+,,-./*012345-678*4509:;?@ABC./$! -.!/0123456*+!789:6;?@A2B!#$6CD

More information

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2013 Section:

More information

Additional radiation boost to whole brain radiation therapy may improve the survival of patients with brain metastases in small cell lung cancer

Additional radiation boost to whole brain radiation therapy may improve the survival of patients with brain metastases in small cell lung cancer Sun et al. Radiation Oncology (2018) 13:250 https://doi.org/10.1186/s13014-018-1198-4 RESEARCH Open Access Additional radiation boost to whole brain radiation therapy may improve the survival of patients

More information

Update on management of metastatic brain disease. Peter Hoskin Mount Vernon Cancer Centre Northwood UK

Update on management of metastatic brain disease. Peter Hoskin Mount Vernon Cancer Centre Northwood UK Update on management of metastatic brain disease Peter Hoskin Mount Vernon Cancer Centre Northwood UK Incidence 15-30% of patients with solid tumours will develop brain metastases Most common primary sites

More information

Ryoko Suzuki 1, Xiong Wei 1, Pamela K. Allen 1, James W. Welsh 1, James D. Cox 1, Ritsuko Komaki 1 and Steven H. Lin 1,2*

Ryoko Suzuki 1, Xiong Wei 1, Pamela K. Allen 1, James W. Welsh 1, James D. Cox 1, Ritsuko Komaki 1 and Steven H. Lin 1,2* Suzuki et al. Radiation Oncology (2018) 13:258 https://doi.org/10.1186/s13014-018-1205-9 RESEARCH Open Access Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain

More information

Sergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy

Sergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26

More information

Pre-operative stereotactic radiosurgery treatment is preferred to post-operative treatment for smaller solitary brain metastases

Pre-operative stereotactic radiosurgery treatment is preferred to post-operative treatment for smaller solitary brain metastases Aliabadi et al. Chinese Neurosurgical Journal (2017) 3:29 DOI 10.1186/s41016-017-0092-5 CHINESE NEUROSURGICAL SOCIETY RESEARCH CHINESE MEDICAL ASSOCIATION Pre-operative stereotactic radiosurgery treatment

More information

Surgical Management of Brain Metastases

Surgical Management of Brain Metastases Surgical Management of Brain Metastases Christopher P. Kellner, MD a, Anthony L. D Ambrosio, MD a,b,c, * KEYWORDS Brain Management Metastasis Metastases Resection Surgery Secondary metastases to the brain

More information

CNS Metastases in Breast Cancer

CNS Metastases in Breast Cancer Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer CNS Metastases in Breast Cancer CNS Metastases in Breast Cancer Version 2006: Maass / Junkermann Version 2007 2009: Bischoff

More information

Jefferson Digital Commons. Thomas Jefferson University. Mark E Linskey Department of Neurosurgery, University of California-Irvine Medical Center

Jefferson Digital Commons. Thomas Jefferson University. Mark E Linskey Department of Neurosurgery, University of California-Irvine Medical Center Thomas Jefferson University Jefferson Digital Commons Department of Neurosurgery Faculty Papers Department of Neurosurgery 1-1-2010 The role of stereotactic radiosurgery in the management of patients with

More information

Management of Brain Metastases Sanjiv S. Agarwala, MD

Management of Brain Metastases Sanjiv S. Agarwala, MD Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):

More information

Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications

Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications Japanese Journal of Clinical Oncology, 2015, 45(8) 713 718 doi: 10.1093/jjco/hyv067 Advance Access Publication Date: 15 May 2015 Original Article Original Article Prolonged survival after diagnosis of

More information

Radiotherapy for Brain Metastases

Radiotherapy for Brain Metastases Radiotherapy for Brain Metastases Robert B. Den, MD a, David W. Andrews, MD b, * KEYWORDS Brain metastases Treatment approaches SRS WBRT The optimal treatment of brain metastases remains controversial.

More information

After primary tumor treatment, 30% of patients with malignant

After primary tumor treatment, 30% of patients with malignant ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant

More information

Cerebral metastases occur in 20% 40% of cancer

Cerebral metastases occur in 20% 40% of cancer See the corresponding editorial, DOI: 10.3171/2012.1.JNS12103. DOI: 10.3171/2012.4.JNS11870 Stereotactic radiosurgery using the Leksell Gamma Knife Perfexion unit in the management of patients with 10

More information

Factors influencing survival in patients with breast cancer and single or solitary brain metastasis

Factors influencing survival in patients with breast cancer and single or solitary brain metastasis Factors influencing survival in patients with breast cancer and single or solitary brain metastasis A. Niwińska, K. Pogoda, M. Murawska, P. Niwiński To cite this version: A. Niwińska, K. Pogoda, M. Murawska,

More information

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2015

More information

Prescription dose and fractionation predict improved survival after stereotactic radiotherapy for brainstem metastases

Prescription dose and fractionation predict improved survival after stereotactic radiotherapy for brainstem metastases Leeman et al. Radiation Oncology 2012, 7:107 RESEARCH Open Access Prescription dose and fractionation predict improved survival after stereotactic radiotherapy for brainstem metastases Jonathan E Leeman

More information

Surgical treatment of multiple brain metastases

Surgical treatment of multiple brain metastases J Neurosurg 79:210-216, 1993 Surgical treatment of multiple brain metastases RAJESH K. BINDAL, B.A., RAYMOND SAWAYA, M.D., MILAM E. LEAVENS, M.D., ANO J. JACK LEE, PH.D. Departments of Neurosurgery and

More information

CME. Special Article. Received 27 October 2011; revised 9 December 2011; accepted 15 December Practical Radiation Oncology (2012) 2,

CME. Special Article. Received 27 October 2011; revised 9 December 2011; accepted 15 December Practical Radiation Oncology (2012) 2, Practical Radiation Oncology (2012) 2, 210 225 CME www.practicalradonc.org Special Article Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation

More information

Introduction ORIGINAL RESEARCH

Introduction ORIGINAL RESEARCH Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey

More information

Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva

Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer

More information

Title: Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death

Title: Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death Author's response to reviews Title: Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death Authors: Romuald Le Scodan (lescodan@crh1.org)

More information

ORIGINAL ARTICLE. Annals of Oncology 28: , 2017 doi: /annonc/mdx332 Published online 27 June 2017

ORIGINAL ARTICLE. Annals of Oncology 28: , 2017 doi: /annonc/mdx332 Published online 27 June 2017 Annals of Oncology 28: 2588 2594, 217 doi:1.193/annonc/mdx332 Published online 27 June 217 ORIGINAL ARTICLE Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients

More information

Br a i n metastases are the tumors most frequently. Safety and efficacy of Gamma Knife surgery for brain metastases in eloquent locations

Br a i n metastases are the tumors most frequently. Safety and efficacy of Gamma Knife surgery for brain metastases in eloquent locations J Neurosurg 113:79 83, 2010 Safety and efficacy of Gamma Knife surgery for brain metastases in eloquent locations Clinical article Ni c o l a s De a, M.D., Mar t i n Bo r d u a s, Br e n d a n Ke n n y,

More information

ARROCase Brain Metastases

ARROCase Brain Metastases ARROCase Brain Metastases Colin Hill*, Daniel M. Trifiletti*, Timothy N. Showalter*, Jason P. Sheehan Radiation Oncology* and Neurosurgery University of Virginia Charlottesville, VA Case: HPI 64 year old

More information

Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy

Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo

More information

Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer

Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer Kaul et al. Radiation Oncology (2015) 10:244 DOI 10.1186/s13014-015-0550-1 RESEARCH Open Access Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer David Kaul

More information

A new score predicting the survival of patients with spinal cord compression from myeloma

A new score predicting the survival of patients with spinal cord compression from myeloma Douglas et al. BMC Cancer 2012, 12:425 RESEARCH ARTICLE Open Access A new score predicting the survival of patients with spinal cord compression from myeloma Sarah Douglas 1, Steven E Schild 2 and Dirk

More information

Clinical Study Does Time between Imaging Diagnosis and Initiation of Radiotherapy Impact Survival after Whole-Brain Radiotherapy for Brain Metastases?

Clinical Study Does Time between Imaging Diagnosis and Initiation of Radiotherapy Impact Survival after Whole-Brain Radiotherapy for Brain Metastases? ISRN Oncology Volume 2013, Article ID 214304, 4 pages http://dx.doi.org/10.1155/2013/214304 Clinical Study Does Time between Imaging Diagnosis and Initiation of Radiotherapy Impact Survival after Whole-Brain

More information

Gamma surgery for intracranial metastases from renal cell carcinoma

Gamma surgery for intracranial metastases from renal cell carcinoma J Neurosurg 92:760 765, 2000 Gamma surgery for intracranial metastases from renal cell carcinoma BRYAN RANKIN PAYNE, M.D., DHEERENDRA PRASAD, M.D., GYÖRGY SZEIFERT, M.D., PH.D., MELITA STEINER, M.D., AND

More information

Gamma Knife Radiosurgery A tool for treating intracranial conditions. CNSA Annual Congress 2016 Radiation Oncology Pre-congress Workshop

Gamma Knife Radiosurgery A tool for treating intracranial conditions. CNSA Annual Congress 2016 Radiation Oncology Pre-congress Workshop Gamma Knife Radiosurgery A tool for treating intracranial conditions CNSA Annual Congress 2016 Radiation Oncology Pre-congress Workshop ANGELA McBEAN Gamma Knife CNC State-wide Care Coordinator Gamma Knife

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Management of Brain Metastases Dr. Luis Souhami Professor Department of Radiation Oncology University,

More information

Brain metastases arise in 10% 40% of patients

Brain metastases arise in 10% 40% of patients J Neurosurg (Suppl) 117:38 44, 2012 Validation of Recursive Partitioning Analysis and Diagnosis-Specific Graded Prognostic Assessment in patients treated initially with radiosurgery alone Clinical article

More information

Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care

Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland

More information

Treatment of Brain Metastases

Treatment of Brain Metastases 1 Treatment of Brain Metastases An Overview and Pending Research Questions To Answer Olav E. Yri, MD, PhD www.ntnu.no/prc European Palliative Care Research Centre (PRC) The brain metastases diagnosis Outline

More information

Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer

Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,

More information

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 04/01/2014 Section:

More information

Mehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey

Mehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey Updated Oncology 2015: State of the Art News & Challenging Topics CURRENT STATUS OF STEREOTACTIC RADIOSURGERY IN BRAIN METASTASES Mehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey Bucharest,

More information

Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?

Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Department of Radiation Oncology Chairman: Prof. Dr. Matthias Guckenberger Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen? Matthias

More information

Is it cost-effective to treat brain metastasis with advanced technology?

Is it cost-effective to treat brain metastasis with advanced technology? Is it cost-effective to treat brain metastasis with advanced technology? Cost-effectiveness analysis of whole brain RT, stereotactic radiosurgery and craniotomy in HA setting Lam, Tai-Chung, Choi CW Horace,

More information

INTRODUCTION. Tae Yong Park, Young Chul Na, Won Hee Lee, Ji Hee Kim, Won Seok Chang, Hyun Ho Jung, Jong Hee Chang, Jin Woo Chang, Young Gou Park

INTRODUCTION. Tae Yong Park, Young Chul Na, Won Hee Lee, Ji Hee Kim, Won Seok Chang, Hyun Ho Jung, Jong Hee Chang, Jin Woo Chang, Young Gou Park ORIGINAL ARTICLE Brain Tumor Res Treat 2013;1:78-84 / Print ISSN 2288-2405 / Online ISSN 2288-2413 online ML Comm Treatment Options of Metastatic Brain Tumors from Hepatocellular Carcinoma: Surgical Resection

More information

Place of surgery in diagnos1c and therapeu1c strategies: New challenges

Place of surgery in diagnos1c and therapeu1c strategies: New challenges Place of surgery in diagnos1c and therapeu1c strategies: New challenges Philippe Métellus M.D., Ph.D. Department of Neurosurgery, CHU Timone, Marseille, France Place of surgery in diagnos1c and therapeu1c

More information

Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer

Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative

More information

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy

Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 11/20/2015

More information

CONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND

CONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 CONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND EVIDENCE-BASED PRACTICE GUIDELINE ON THE ROLE OF SURGERY IN THE MANAGEMENT

More information

The incidence of malignant melanoma is among the. Surgical management of melanoma brain metastases in patients treated with immunotherapy

The incidence of malignant melanoma is among the. Surgical management of melanoma brain metastases in patients treated with immunotherapy J Neurosurg 115:30 36, 2011 Surgical management of melanoma brain metastases in patients treated with immunotherapy Clinical article Russell R. Lonser, M.D., 1 Debbie K. Song, M.D., 1 Jacob Klapper, M.D.,

More information

Protocolos de consenso: MTS Cerebrales Resumen ASTRO. Javier Aristu y Germán Valtueña Servicio Oncología Rad. Depart.

Protocolos de consenso: MTS Cerebrales Resumen ASTRO. Javier Aristu y Germán Valtueña Servicio Oncología Rad. Depart. Protocolos de consenso: MTS Cerebrales Resumen ASTRO Javier Aristu y Germán Valtueña Servicio Oncología Rad. Depart. ASTRO 2013 Brain met SRS Abstracts 97. Comparative Effectiveness of SRS versus WBRT

More information

Clinical Commissioning Policy: Stereotactic Radiosurgery / Radiotherapy For Cerebral Metastases. December Reference : NHSCB/D5/1

Clinical Commissioning Policy: Stereotactic Radiosurgery / Radiotherapy For Cerebral Metastases. December Reference : NHSCB/D5/1 Clinical Commissioning Policy: Stereotactic Radiosurgery / Radiotherapy For Cerebral Metastases December 2012 Reference : NHSCB/D5/1 NHS Commissioning Board Clinical Commissioning Policy: Stereotactic

More information

Key words: brain neoplasms; lung neoplasms; neoplasm metastasis; neurosurgery; survival rate; thoracic surgery

Key words: brain neoplasms; lung neoplasms; neoplasm metastasis; neurosurgery; survival rate; thoracic surgery Surgical Management of Non-small Cell Lung Cancer With Synchronous Brain Metastases* Pierre Bonnette, MD; Philippe Puyo, MD; Christophe Gabriel, MD; Roger Giudicelli, MD; Jean-François Regnard, MD; Marc

More information

See the corresponding editorial in this issue, pp J Neurosurg 114: , 2011

See the corresponding editorial in this issue, pp J Neurosurg 114: , 2011 See the corresponding editorial in this issue, pp 790 791. J Neurosurg 114:792 800, 2011 Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer Clinical article

More information

Clinical significance of conformity index and gradient index in patients undergoing stereotactic radiosurgery for a single metastatic tumor

Clinical significance of conformity index and gradient index in patients undergoing stereotactic radiosurgery for a single metastatic tumor CLINICAL ARTICLE J Neurosurg (Suppl) 129:103 110, 2018 Clinical significance of conformity index and gradient index in patients undergoing stereotactic radiosurgery for a single metastatic tumor Hitoshi

More information

Evidence Based Medicine for Gamma Knife Radiosurgery. Metastatic Disease GAMMA KNIFE SURGERY

Evidence Based Medicine for Gamma Knife Radiosurgery. Metastatic Disease GAMMA KNIFE SURGERY GAMMA KNIFE SURGERY Metastatic Disease Evidence Based Medicine for Gamma Knife Radiosurgery Photos courtesy of Jean Régis, Timone University Hospital, Marseille, France Brain Metastases The first report

More information

Metastasi cerebrali La Radioterapia: tecnica, frazionamento, radiosensibilizzanti

Metastasi cerebrali La Radioterapia: tecnica, frazionamento, radiosensibilizzanti Metastasi cerebrali La Radioterapia: tecnica, frazionamento, radiosensibilizzanti Brain Metastases Radiation Therapy of multiple brain metastases Is treatment appropriate? - Survival - QoL Brain Metastases

More information